Recent developments in the treatment of age-related macular degeneration

被引:178
作者
Holz, Frank G. [1 ]
Schmitz-Valckenberg, Steffen [1 ]
Fleckenstein, Monika [1 ]
机构
[1] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany
关键词
ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT FACTOR-H; GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION; RANIBIZUMAB; RISK; VEGF; BLINDNESS; THERAPY; VARIANT;
D O I
10.1172/JCI71029
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Age-related macular degeneration (AMD) is a common cause of visual loss in the elderly, with increasing prevalence due to increasing life expectancy. While the introduction of anti-VEGF therapy has improved outcomes, there are still major unmet needs and gaps in the understanding of underlying biological processes. These include early, intermediate, and atrophic disease stages. Recent studies have assessed therapeutic approaches addressing various disease-associated pathways, including complement inhibitors. Drug-delivery aspects are also relevant, as many agents have to be administered repeatedly. Herein, relevant pathogenetic factors and underlying mechanisms as well as recent and potential therapeutic approaches are reviewed.
引用
收藏
页码:1430 / 1438
页数:9
相关论文
共 85 条
[1]  
Barakat M, 2013, AGE RELATED MACULAR
[2]   Time Trends in the Incidence and Causes of Blindness in Israel [J].
Belkin, Michael ;
Kalter-Leibovici, Ofra ;
Chetrit, Angela ;
Skaat, Alon .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 155 (02) :404-404
[3]   Incidence of Legal Blindness From Age-Related Macular Degeneration in Denmark: Year 2000 to 2010 [J].
Bloch, Sara Brandi ;
Larsen, Michael ;
Munch, Inger Christine .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 153 (02) :209-213
[4]   The dynamic nature of Bruch's membrane [J].
Booij, J. C. ;
Baas, D. C. ;
Beisekeeva, J. ;
Gorgels, T. G. M. F. ;
Bergen, A. A. B. .
PROGRESS IN RETINAL AND EYE RESEARCH, 2010, 29 (01) :1-18
[5]  
Boulton M.E., 2013, Age-related Macular Degeneration, P45
[6]  
Boyer D, 2013, INVEST OPHTH VIS SCI, V54
[7]   Ranibizumab versus verteporfin for neovascular age-related macular degeneration [J].
Brown, David M. ;
Kaiser, Peter K. ;
Michels, Mark ;
Soubrane, Gisele ;
Heier, Jeffrey S. ;
Kim, Robert Y. ;
Sy, Judy P. ;
Schneider, Susan .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (14) :1432-1444
[8]   Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration [J].
Busbee, Brandon G. ;
Ho, Allen C. ;
Brown, David M. ;
Heier, Jeffrey S. ;
Suner, Ivan J. ;
Li, Zhengrong ;
Rubio, Roman G. ;
Lai, Phillip .
OPHTHALMOLOGY, 2013, 120 (05) :1046-1056
[9]  
Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
[10]  
Cayouette M, 1998, J NEUROSCI, V18, P9282